

(This is only an advertisement for information purposes and is not a prospectus announcement)



SHELTER PHARMA LIMITED

Corporate Identification Number: U24233GJ2007PLC051956

Our Company was originally converted from a Partnership Firm "M/s Shelter Pharma" to a Public Limited Company on October 12, 2007 as "Shelter Pharma Limited" under the provisions of the Companies Act, 1956 with the Registrar of Companies, Gujarat, Dadra and Nagar Haveli. The Corporate Identification Number of our Company is U24233GJ2007PLC051956. For further details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 116 of the Prospectus.

Registered Office: Shelter Nagar, Near S. T. Bus Stand, Himmatnagar - 383001, Gujarat, India.
Tel: 02772296038 | E-mail: info@shelter.co.in | Website: www.shelter.co.in

Contact Person: Mr. Mustaqim Nisar Ahmed Sabugar, Managing Director

PROMOTER OF OUR COMPANY: MR. MUSTAQIM NISAR AHMED SABUGAR AND MR. SHAKIL NISAR AHMED SABUGAR

THE ISSUE

PUBLIC ISSUE OF 38,16,000 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES") OF SHELTER PHARMA LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹42.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹32.00 PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹1,602.72 ("THE ISSUE") OF WHICH 1,92,000 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH FOR CASH AT A PRICE OF ₹42.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹32.00 PER EQUITY SHARE AGGREGATING TO ₹80.64 LAKH WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 36,24,000 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH AT A PRICE OF ₹42.00 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹32.00 PER EQUITY SHARE AGGREGATING TO ₹1,522.08 LAKH (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 33.01% AND 31.35% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS ₹10.00 AND THE ISSUE PRICE IS 4.2 TIMES OF THE FACE VALUE OF THE EQUITY SHARES

THIS ISSUE IS BEING MADE IN TERMS OF REGULATION 229(2) AND 253(1) OF CHAPTER IX OF THE SEBI (ICDR) REGULATIONS, 2018 AS AMENDED.

ISSUE OPENS ON: THURSDAY, AUGUST 10, 2023
CLOSES ON: MONDAY, AUGUST 14, 2023

FIXED PRICE ISSUE AT ₹42.00 PER EQUITY SHARE

MINIMUM APPLICATION SIZE OF 3,000 EQUITY SHARES AND IN MULTIPLES OF 3,000 EQUITY SHARES THEREAFTER

ASBA *Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For further details check section on ASBA below. Mandatory in Public Issues from January 01, 2016. No cheque will be accepted.

UPI - Now mandatory in ASBA for Retail Investors applying through Registered Brokers, DPs & RTAs. Retail Investors also have the options to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Applicants should ensure that DP ID, PAN and the Client ID are correctly filled in the Application Form. The DP ID, PAN and Client ID provided in the Application Form should match with the DP ID and Client ID available in the Depository database, otherwise, the Application Form is liable to be rejected. Applicant should ensure that the beneficiary account provided in the Application Form is active. Applicants should note that on the basis of the PAN, DP ID and Client ID as provided in the Application Form, the Applicant may be deemed to have authorized the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for any correspondence(s) related to the Issue. Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants' sole risk.

APPLICATIONS SUPPORTED BY BLOCKED AMOUNT (ASBA): Investors have to compulsorily apply through the ASBA process. ASBA has to be availed of by all investors. Further as per SEBI Circular SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, all Retail Individual Investors can also apply through Unified Payments Interface ("UPI"). The investor is required to fill the Application form and submit the same to the relevant SCSB or the Registered Brokers at Broker Center or the RTA or the CDP. The SCSB will block the amount in the account as per the authority contained in Application form and undertake other tasks as per the specified procedure. On allotment, amount will be unblocked and account will be debited only to the extent required to be paid for Allotment of Equity Shares. Hence, there will be no need for refunds. For more details on the ASBA process, please refer to the section, "Issue Procedure" beginning on page no. 202 of the Prospectus.

RISKS IN RELATION TO FIRST ISSUE: This being the first Public Issue of our Company, there has been no formal market for the Equity Shares of our Company. The face value of the equity shares is ₹10.00. The Issue Price (as determined and justified by our Company in consultation with the Lead Manager as stated in "Basis for Issue Price" on page no. 76 of the Prospectus) should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this offering. For taking an investment decision, investors must rely on their own examination of the Issuer and the Issue including the risks involved. The Equity Shares in the Issue have neither been recommended nor approved by Securities and Exchange Board of India (SEBI) nor does SEBI guarantee the accuracy or adequacy of the Prospectus. Specific attention of the investors is invited to the section titled "Risk Factors" beginning on page no. 25 of the Prospectus.

ISSUER'S ABSOLUTE RESPONSIBILITY: Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that the Prospectus contains all information with regard to our Company and the Issue which is material in the context of the Issue, that the information contained in the Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes the Prospectus as a whole or any of such information or the expression of any such opinions or intentions misleading, in any material respect.

LISTING: The Equity Shares issued through the Prospectus are proposed to be listed on the SME Platform of BSE Limited. Our Company has received 'in-principle' approvals from BSE for the listing of the Equity Shares pursuant to letter dated June 30, 2023. For the purposes of the Issue, the Designated Stock Exchange shall be BSE Limited.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA: Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Prospectus will be filed with SEBI in terms of the Regulation 246 (5) of the SEBI (ICDR) Regulations, 2018, and the SEBI shall not offer any observation on our Document. Hence, there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire "Disclaimer Clause of SEBI" on page no. 184 of the Prospectus.

DISCLAIMER CLAUSE OF THE SME PLATFORM OF BSE (DESIGNATED STOCK EXCHANGE): "It is to be distinctly understood that the permission given by BSE Limited ("BSE") should not in any way be deemed or construed that the contents of the Prospectus or the price at which the equity shares are offered has been cleared, solicited or approved by BSE, nor does it certify the correctness, accuracy or completeness of any of the contents of the Prospectus. The investors are advised to refer to the Prospectus for the full text of the "Disclaimer clause of the SME Platform of BSE Limited" on page no.186 of the Prospectus.

ADDITIONAL INFORMATION AS REQUIRED UNDER SECTION 30 OF THE COMPANIES ACT, 2013
MAIN OBJECTS AS PER MEMORANDUM OF ASSOCIATION OF THE COMPANY: For information on the main objects of our Company, see "Our History and Certain Other Corporate Matters" on page no. 116 of the Prospectus and Clause III (A) of the Memorandum of Association of our Company is a material document for inspection in relation to the Issue.

LIABILITY OF MEMBERS: The Liability of members of Company is Limited.
AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: Authorized Share Capital of ₹15,00,00,000 divided into 1,50,00,000 Equity Shares of ₹10.00 each. Issued, Subscribed & Paid-up Share Capital prior to the Issue: ₹7,74,37,920 divided into 77,43,792 Equity Shares of ₹10.00 each. Proposed Post Issue Paid-up Share Capital: ₹11,55,97,920 divided into 1,15,59,792 Equity Shares of ₹10.00 each.

Signatories to MOA		Current Promoters	
Name	No. of shares	Name	No. of shares
Mr. Nisar Ahmed A. Sabugar	40,000	Mr. Mustaqim Nisar Ahmed Sabugar	14,56,000
Mr. Mustaqim Nisar Ahmed Sabugar	1,00,000	Mr. Shakil Nisar Ahmed Sabugar	17,80,000
Mr. Shakil Nisar Ahmed Sabugar	1,00,000		
Ms. Zubeda N. Sabugar	40,000		
Ms. Nasrat M. Sabugar	40,000		
Ms. Suraiya N. Sabugar	40,000		
Ms. Parvezbanu R. Idariya	40,000		
Total	4,00,000	Total	32,16,000

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 GRETEX CORPORATE SERVICES LIMITED Office No. 13, 1st Floor, New Banisali Building, Raja Bahadur Mansion, 9-15, Homi Modi Street, Fort, Mumbai - 400 001 Tel No.: +91 96532 49863 Email: info@gretexgroup.com Website: www.gretexgroup.com Contact Person: Ms. Dimple Magharam Slun SEBI Registration No: INM000012177 CIN: L74999MH2008PLC286128	 BIGSHARE SERVICES PRIVATE LIMITED Office No. S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri East, Mumbai - 400 093, Maharashtra, India Tel. No.: +91 - 22 - 6263 8200; Fax No.: +91 - 22 - 6263 8299 Email: ipo@bigshareonline.com; Website: www.bigshareonline.com Investor Grievance Email: investor@bigshareonline.com Contact Person: Mr. Swapnil Kate SEBI Registration No.: INR000001385 CIN: U99999MH1994PTC076534	 SHELTER PHARMA LIMITED Mr. Yashesh Vijaykumar Shah Company Secretary and Compliance Officer, Shelter Nagar, Near S. T. Bus Stand, Himmatnagar - 383001, Gujarat, India Tel No.: 02772296038 E-mail: info@shelter.co.in Website: http://www.shelter.co.in Investors can contact the Compliance Officer or the Registrar to the Issue in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, credit of allotted shares in the respective beneficiary account, etc.

AVAILABILITY OF APPLICATION FORMS: Application Form can be obtained from the Registered Office of Company, SHELTER PHARMA LIMITED; Registered Office of Lead Manager: GRETEX CORPORATE SERVICES LIMITED, Email: info@gretexgroup.com, Tel No.: +91 96532 49863; Self Certified Syndicate Banks; Registered Brokers; Designated RTA Locations and Designated CDP Locations for participating in the Issue. Application Forms will also be available on the websites of the Stock Exchange and at all the Designated Branches of SCSBs, the list of which is available on the websites of the Stock Exchange and SEBI.

AVAILABILITY OF PROSPECTUS: Investors should note that investment in Equity Shares involves a degree of risk and investors are advised to refer to the Prospectus and the Risk Factors contained therein, before applying in the Issue. Full copy of the Prospectus shall be available at the website of Stock Exchange at www.bsesme.com, the website of Lead Manager at www.gretexgroup.com and the website of the Issuer Company at http://www.shelter.co.in/

BANKER TO THE ISSUE & SPONSOR BANK: ICICI Bank Limited
All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus dated August 05, 2023.

FOR SHELTER PHARMA LIMITED
Sd/-
Mustaqim Nisar Ahmed Sabugar
Managing Director
DIN: 01456841

SHELTER PHARMA LIMITED is proposing, subject to market conditions and other considerations, public issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Ahmedabad. The Prospectus is available on the website of the Lead Manager at www.gretexgroup.com and the website of the BSE Limited i.e., www.bsesme.com, and website of the Issuer Company at http://www.shelter.co.in/ Investors should note that investment in Equity Shares involves a high degree of risk. For details investors should refer to and rely on the Prospectus including the section titled "Risk Factors" beginning on page no. 25 of the Prospectus, which has been filed with ROC.

The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be offered and sold (i) in the United States only to "qualified institutional buyers", as defined in Rule 144A of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and in compliance with the applicable laws of the jurisdiction where those offers and sales occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

GAYATRI SUGARS LIMITED

Regd. & Corp. Office: 6-3-1090, B-2, T.S.R. Towers, Rajbhavan Road, Somajiguda, Hyderabad - 500 082, Telangana, India. Tel: +91 40 2341 4823, 2331 4826 Fax: +91 40 2341 4827
E mail: compliance.gayatrisugars@gayatri.co.in CIN: L15421TG1995PLC020720

Extract of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2023

PARTICULARS	Quarter ended	Quarter ended	Quarter ended	Year ended
	30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
Total Income from Operations	5,781.50	22,665.55	5,011.16	38,831.38
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extra Ordinary Items)	(1,084.62)	4,143.37	(1,494.88)	846.69
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	(1,084.62)	6,728.87	(1,494.88)	3,432.19
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	(1,084.62)	6,728.87	(1,494.88)	3,432.19
Total comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other comprehensive Income (after tax)]	(1,090.08)	6,813.06	(1,512.64)	3,463.09
Equity Share Capital	4,370.05	4,370.05	4,370.05	4,370.05
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	(16,789.20)
Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations)				
Basic (in ₹) :	(2.48)	15.39	(3.42)	7.85
Diluted (in ₹) : (*antidilutive)	(2.48)	7.93	(3.42)	4.05

Note:
1. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 7th August 2023
2. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange website i.e. BSE Limited at www.bseindia.com and on Company website: www.gayatrisugars.com

By Order of the Board
For Gayatri Sugars Limited
Sd/- T. Sarita Reddy
Managing Director
(DIN: 00017122)

Place: Hyderabad
Date : 07.08.2023

For All Advertisement Booking
Call : 0120-6651214

Krishna Institute of Medical Sciences Limited
Corporate Identity Number: L551011TG1973PLC040558
Registered office: 1-8-31/1, Minister Road, Secunderabad - 500003, Telangana, India
Website: www.kimshospitals.com, Email: cs@kimshospitals.com, Tel: 040 7122 5000



STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2023

S.No	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		30-Jun-23 (Unaudited)	31-Mar-23 (Audited)	30-Jun-22 (Unaudited)	31-Mar-23 (Audited)	30-Jun-23 (Unaudited)	31-Mar-23 (Audited)	30-Jun-22 (Unaudited)	31-Mar-23 (Audited)
1	Income	3,027.39	2,983.24	2,666.57	11,555.20	6,091.41	5,808.13	5,008.49	22,235.50
2	Net profit (Before tax and Exceptional items)	839.77	979.65	700.20	3,373.33	1,185.79	1,272.69	1,073.55	4,700.78
3	Net profit before tax (after Exceptional items)	839.77	979.65	700.20	3,373.33	1,185.79	1,272.69	1,073.55	4,849.07
4	Net profit after tax (after tax and Exceptional items)	626.34	746.97	521.22	2,524.89	866.71	986.73	792.45	3,658.13
5	Total comprehensive income for the year (Comprising income for the year (after tax) and other comprehensive income (after tax))	628.40	748.30	521.71	2,523.12	868.50	989.62	795.19	3,666.64
6	Equity share capital (Face value of Rs. 10/- each)	800.28	800.28	800.28	800.28	800.28	800.28	800.28	800.28
7	Reserves (excluding revaluation reserve)	16,136.71	15,508.31	13,496.91	15,508.31	16,651.36	15,895.10	13,773.99	15,895.10
8	Earnings per share (Face value of Rs. 10/- Each) (not annualised)								
	(a) Basic (Rs.)	7.83	9.33	6.51	31.55	10.10	11.65	8.74	42.03
	(b) Diluted (Rs.)	7.83	9.33	6.51	31.55	10.10	11.65	8.74	42.03

Note: 1. The above is an extract of detailed Unaudited Financial Results filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results for the quarter ended 30.06.2023 are available on Stock Exchange's website www.bseindia.com, www.nseindia.com and on Company's website at www.kimshospitals.com. 2. The above results of the Company have been reviewed by the audit committee and approved by the Board of Directors at their meeting held on 07.08.2023.

By Order of the Board
For Krishna Institute of Medical Sciences Limited
Dr. B. Bhaskara Rao
Chairman & Managing Director
DIN: 00008985

Place: Hyderabad
Date: 07 Aug 2023

MADHYA BHARAT AGRO PRODUCTS LTD.

OSTWAL Reg. Office- 5-O-21, Basement, R.C. Vyas Colony, Bhilwara (Raj.) India
Website: www.mbapl.com Email: secretarial@mbapl.com; CIN : L24121RJ1997PLC029126
Tel. No. : 01482-237104, Fax No. : 01482-239638

Extract of Un-Audited Financial Results For the Quarter ended 30th June, 2023 [Regulation 47(1)(b) of the SEBI (LODR) Regulations, 2015]

S. No.	Particulars	Quarter ended		Year Ended	
		30.06.2023 Unaudited	31.03.2023 Audited	30.06.2022 Unaudited	31.03.2023 Audited
1	Total income from operations	15,008.78	23,498.00	21,308.81	98,723.91
2	Net profit / (loss) for the period (before tax, exceptional and extraordinary items)	1,242.60	3,404.00	4,060.42	17,616.90
3	Net profit / (loss) for the period before tax (after exceptional and extraordinary items)	1,242.60	3,404.00	4,060.42	17,616.90
4	Net profit / (loss) for the period after tax (after exceptional and extraordinary items)	723.81	2,427.46	2,866.59	12,420.37
5	Total comprehensive income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	723.81	2,423.39	2,866.59	12,416.30
6	Equity share capital	4,381.35	4,381.35	2,190.67	4,381.35
7	Other equity (Reserves)	-	-	-	28,457.14
8	Earning per share (of Rs. 10/- each) (for continuing and discontinued operations) (not annualised)				
	1. Basic (Restated)	1.65	5.54	6.54	28.35
	2. Diluted (Restated)	1.65	5.54	6.54	28.35

Note :
a) The above unaudited financial results of the company for the quarter ended June 30th, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 7th August, 2023. The same have been subjected to limited review by the Statutory Auditors.
b) The above financial results are prepared in accordance with Indian Accounting Standards ("IND AS") as prescribed under section 133 of the companies Act, 2013 read with relevant rules issued there under.
c) The above is an extract of the detailed financial results for the Quarter ended 30th June, 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results are available on the websites of the Stock Exchange www.nseindia.com and Company's website www.mbapl.com

For and on behalf of the Board of Directors
Souabh Gupta
Director & CFO
DIN 07177647

Place: Bhilwara
Date : 7th August ,2023

